Journal article

Preoperative Chemoradiotherapy for Resectable Gastric Cancer

T Leong, BM Smithers, M Michael, K Haustermans, R Wong, V Gebski, RL O’Connell, J Zalcberg, A Boussioutas, M Findlay, D Willis, A Moore, WK Murray, F Lordick, C O’Callaghan, C Swallow, G Darling, D Miller, A Strickland, M Liberman Show all

New England Journal of Medicine | Published : 2024

Abstract

BACKGROUND In Western countries, the current standard of care for resectable gastric cancer is perioperative chemotherapy. Preoperative chemoradiotherapy has been considered, but data are limited regarding this treatment as compared with perioperative chemotherapy alone. METHODS We conducted an international, phase 3 trial in which patients with resectable adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to receive preoperative chemoradiotherapy plus perioperative chemotherapy or perioperative chemotherapy alone (control). In both groups, patients received either epirubicin, cisplatin, and fluorouracil or fluorouracil, leucovorin, oxaliplatin, and docetaxel b..

View full abstract

University of Melbourne Researchers